The University of Tennessee is a public land-grant research university in Knoxville, Tennessee. Founded in 1794, two years before Tennessee became the 16th state, it is the flagship campus of the University of Tennessee system, with ten undergraduate colleges and eleven graduate colleges.

During the past decade, University of Tennessee, Knoxville conducted 53 clinical trials. In the 10-year time frame, 53 clinical trials started and 56 clinical trials were completed, i.e. on average, 105.7% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 29 clinical trials were completed. i.e. 116% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Tennessee, Knoxville" #1 sponsor was "National Cancer Institute (NCI)" with 45 trials, followed by "The University of Tennessee, Knoxville" with 26 trials sponsored, "Alliance for Clinical Trials in Oncology" with 8 trials sponsored, "Gynecologic Oncology Group" with 6 trials sponsored and "SWOG Cancer Research Network" with 6 trials sponsored. Other sponsors include 40 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Tennessee, Knoxville" #1 collaborator was "National Cancer Institute (NCI)" with 32 trials as a collaborator, "NRG Oncology" with 8 trials as a collaborator, "Cancer and Leukemia Group B" with 5 trials as a collaborator, "SWOG Cancer Research Network" with 5 trials as a collaborator and "University of Tennessee" with 4 trials as a collaborator. Other collaborators include 55 different institutions and companies that were collaborators in the rest 54 trials.

According to Clinical.Site data, the most researched conditions in "University of Tennessee, Knoxville" are "Obesity" (10 trials), "Stage IIA Fallopian Tube Cancer AJCC v6 and v7" (6 trials), "Stage IIB Fallopian Tube Cancer AJCC v6 and v7" (6 trials), "Stage IIC Fallopian Tube Cancer AJCC v6 and v7" (6 trials) and "Stage IV Fallopian Tube Cancer AJCC v6 and v7" (6 trials). Many other conditions were trialed in "University of Tennessee, Knoxville" in a lesser frequency.

Most popular intervention types in "University of Tennessee, Knoxville" are "Drug" (79 trials), "Other" (68 trials), "Biological" (33 trials), "Device" (18 trials) and "Procedure" (17 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (31 trials), "Quality-of-Life Assessment" (24 trials), "Paclitaxel" (20 trials), "Carboplatin" (15 trials) and "Bevacizumab" (14 trials). Other intervention names were less common.

The vast majority of trials in "University of Tennessee, Knoxville" are 106 trials for "All" genders, 28 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of Tennessee, Knoxville". 1 are not yet recruiting, 22 are recruiting, 46 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 52 completed trials in University of Tennessee, Knoxville, 2 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in University of Tennessee, Knoxville, 1 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 65 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 29 trials that are defined as “Not Applicable".